Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· April 22, 2026

Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting

View original at globenewswire.com
Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Both programs leverage generative AI platforms to address longstanding limitations of existing cancer therapies, including poor CNS penetrance and the toxicity burden of drug combination regimens

    60% confidence

  • No approved therapy directly addresses the dual ATR-mTOR vulnerability with effective CNS penetrance in PTEN-deficient tumors

    60% confidence

  • kt-3283 clinical viability has been limited by bioavailability and metabolic stability challenges

    60% confidence

  • For the ATR-mTOR program, candidate inhibitors are tracking closely with AI predictions for potency, selectivity, and CNS penetrance

    60% confidence

  • The structured surface and organized phospholipid assembly observed in kt-3283 LNP are precisely the properties expected to enhance nanoparticle stability and cellular uptake

    60% confidence

  • AI-powered discovery approach can evaluate billions of potential drug candidates at a pace not achievable through traditional methods

    60% confidence

  • The in vivo efficacy data for our ATR-mTOR inhibitor are particularly encouraging. The compound demonstrated potency comparable to an established reference compound while exhibiting a meaningfully improved tolerability profile.

    60% confidence

  • Our strategy of integrating AI-guided design with biological validation is working as intended

    60% confidence

  • These results reinforce the potential of our AI-driven pipeline and support a path toward IND-enabling studies

    60% confidence

Cited in these Via News reports